This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Find out more about our recent Conversations in Oncology series of standalone meetings and preceptorship programmes.
Conversations in Oncology
Conversations in Oncology are a series of standalone medical education meetings which focus on bringing clinicans up-to-date with latest advances in the treatment of lung cancer
The Boehringer Ingelheim Preceptorship programme aims to bring oncologists together for a two- to three-day long meeting, to discuss the latest advancements in the management and treatment of cancer patients. Boehringer Ingelheim provides selected oncology societies and Centers of Excellence (CoE) with an unrestricted educational grant/financial support, with the belief that all parties can benefit from the Preceptorship series. If you want to learn more about our Preceptorships and get further material please get in touch with Sandra Lieb.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue